Have a personal or library account? Click to login
Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies Cover

Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies

Radiology and Oncology
Volume 47 (2013): Issue 1 (March 2013)
By: Alessandro Tuzi,  Davide Lombardi,  Diana Crivellari,  Loredana Militello,  Tiziana Perin,  Manuela La Grassa,  Samuele Massarut and  Andrea Veronesi  
Open Access
|Feb 2013
DOI: https://doi.org/10.2478/raon-2013-0012 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 57 - 62
Published on: Feb 1, 2013
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
breast cancer,
docetaxel,
epirubicin,
neoadjuvant chemotherapy
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2013 Alessandro Tuzi, Davide Lombardi, Diana Crivellari, Loredana Militello, Tiziana Perin, Manuela La Grassa, Samuele Massarut, Andrea Veronesi, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.

Previous articleVolume 47 (2013): Issue 1 (March 2013)Next article